
Topotecan1 mg/ml
ZAS Corporation
Topotecan is a topoisomerase I inhibitor anticancer (cytotoxic chemotherapy) agent used under the supervision of an oncologist.
Topotecan is a topoisomerase I inhibitor anticancer (cytotoxic chemotherapy) agent used under the supervision of an oncologist. Its evidence-based indications are:
Topotecan has been studied off-label in other relapsed/refractory solid tumours and paediatric malignancies (e.g., neuroblastoma, rhabdomyosarcoma, Ewing sarcoma) in clinical trial settings; such use should only occur under specialist oncology protocols, as safety and efficacy for these uses are not formally established.
Dosing of Topotecan is indication-specific and calculated by body surface area (BSA, mg/m²). Topotecan must be administered under the supervision of a qualified oncologist, with a baseline and pre-cycle complete blood count (CBC) confirming adequate bone marrow reserve before each dose.
| Indication | Regimen |
|---|---|
| Ovarian cancer / SCLC (single agent) | 1.5 mg/m² by IV infusion over 30 minutes, once daily for 5 consecutive days, repeated every 21 days (subsequent cycles only after neutrophils ≥1,500/mm³, platelets ≥100,000/mm³, and haemoglobin at an acceptable level) |
| Cervical cancer (with cisplatin) | Topotecan 0.75 mg/m²/day IV over 30 minutes on Days 1, 2, and 3, plus cisplatin 50 mg/m² IV on Day 1 only, repeated every 21 days |
See also Dosage, Administration, and Reconstitution sections below for further detail.
Topotecan commonly causes dose-related bone marrow suppression; the most frequent adverse effects seen in clinical trials include:
Patients should report fever, unusual bleeding/bruising, severe fatigue, breathlessness, or signs of infection to their oncology team immediately.
Topotecan is contraindicated in:
Topotecan is not an antibiotic; no antimicrobial stewardship restrictions apply.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.